My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Arvinas, Inc. - Common Stock (NQ:ARVN)

12.59 +0.17 (+1.33%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

November 26, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

November 24, 2025

From Arvinas Inc.

Via GlobeNewswire

Top movers in Tuesday's session ↗

November 18, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

What 4 Analyst Ratings Have To Say About Arvinas ↗

September 17, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 18, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 18, 2025

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗

November 18, 2025

Via Benzinga

Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach ↗

August 07, 2025

Via Stocktwits

These stocks that are showing activity before the opening bell on Tuesday. ↗

November 18, 2025

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Arvinas Inc (NASDAQ:ARVN) Tops Q3 2025 Earnings Estimates and Provides Pipeline Updates ↗

November 05, 2025

Arvinas (ARVN) beat Q3 2025 earnings estimates, with revenue of $41.9M and a smaller-than-expected loss. The biotech also reported strong pipeline progress and a cash runway into 2028.

Via Chartmill

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 05, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

November 03, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

October 29, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 24, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 22, 2025

From Arvinas Inc.

Via GlobeNewswire

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

October 20, 2025

From Arvinas Inc.

Via GlobeNewswire

Forecasting The Future: 7 Analyst Projections For Arvinas ↗

October 15, 2025

Via Benzinga

This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗

October 15, 2025

Via Benzinga

Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 15, 2025

Via Benzinga

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

October 13, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 05, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 01, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

September 17, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

August 29, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

August 08, 2025

From Arvinas Inc.

Via GlobeNewswire

Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates ↗

August 06, 2025

Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.

Via Chartmill

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 06, 2025

From Arvinas Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.